Publications by authors named "Barbara Vogg"

Claim this Profile
C
Corrigendum to "The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab" [Clin Ther. 2024;46:916-926].
Barbara Vogg, Johann Poetzl, Arnd Schwebig, Susmit Sekhar, Alan Kivitz

Clin Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health.
Richard Eastell, Sławomir Jeka, Maryam Lustberg, Colin Edgerton, Paweł Żuchowski, Barbara Vogg

Ther Adv Musculoskelet Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab.
Barbara Vogg, Johann Poetzl, Arnd Schwebig, Susmit Sekhar, Alan Kivitz

Clin Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.
Sławomir Jeka, Eva Dokoupilová, Alan Kivitz, Paweł Żuchowski, Barbara Vogg

J Bone Miner Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
Barbara Vogg, Johann Poetzl, Rachid El Galta, Rainard Fuhr, Arnd Schwebig

Expert Opin Biol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-((2,4)-4-Ethoxy-1-((5-methoxy-7-methyl-1-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.
Nello Mainolfi, Takeru Ehara, Rajeshri G Karki, Karen Anderson, Aengus Mac Sweeney, Barbara Vogg

J Med Chem· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
Ulf Neumann, Mike Ufer, Laura H Jacobson, Marie-Laure Rouzade-Dominguez, Gunilla Huledal, Barbara Vogg

EMBO Mol Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Ulf Neumann, Heinrich Rueeger, Rainer Machauer, Siem Jacob Veenstra, Rainer M Lueoend, Barbara Vogg

Mol Neurodegener· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples.
Johan Gabrielsson, Stephan Hjorth, Barbara Vogg, Stephanie Harlfinger, Pablo Morentin Gutierrez

Eur J Pharm Sci· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient transgenesis in farm animals by lentiviral vectors.
Andreas Hofmann, Barbara Kessler, Sonja Ewerling, Myriam Weppert, Barbara Vogg

EMBO Rep· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis